Phenyl(thio)phosphon(amid)ate
Benzenesulfonamides
as Potent and Selective Inhibitors of Human Carbonic Anhydrases II
and VII Counteract Allodynia in a Mouse Model of Oxaliplatin-Induced
Neuropathy
posted on 2020-05-14, 16:37authored byAlessio Nocentini, Vincenzo Alterio, Silvia Bua, Laura Micheli, Davide Esposito, Martina Buonanno, Gianluca Bartolucci, Sameh M. Osman, Zeid A. ALOthman, Roberto Cirilli, Marco Pierini, Simona Maria Monti, Lorenzo Di Cesare Mannelli, Paola Gratteri, Carla Ghelardini, Giuseppina De Simone, Claudiu T. Supuran
Human carbonic anhydrase
(CA; EC 4.2.1.1) isoforms II and VII are implicated
in neuronal excitation, seizures, and neuropathic pain (NP). Their
selective inhibition over off-target CAs is expected to produce an
anti-NP action devoid of side effects due to promiscuous CA modulation.
Here, a drug design strategy based on the observation of (dis)similarities
between the target CA active sites was planned with benzenesulfonamide
derivatives and, for the first time, a phosphorus-based linker. Potent
and selective CA II/VII inhibitors were identified among the synthesized
phenyl(thio)phosphon(amid)ates 3–22. X-ray crystallography depicted the binding mode of phosphonic acid 3 to both CAs II and VII. The most promising derivatives,
after evaluation of their stability in acidic media, were tested in
a mouse model of oxaliplatin-induced neuropathy. The most potent compound
racemic mixture was subjected to HPLC enantioseparation, and the identification
of the eutomer, the (S)-enantiomer, allowed to halve
the dose totally relieving allodynia in mice.